ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
8.80
+0.10 (1.15%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Company Description
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kristin Yarema |
Contact Details
Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States | |
| Phone | 858 345 6265 |
| Website | inmagenebio.com |
Stock Details
| Ticker Symbol | IMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G207 |
| ISIN Number | US45175G2075 |
| Employer ID | 81-1697316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kristin Yarema | Chief Executive Officer |
| Kristin Yarema | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2025 | 8-K | Current Report |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 10, 2025 | 8-K | Current Report |
| Sep 15, 2025 | EFFECT | Notice of Effectiveness |
| Sep 8, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 12, 2025 | 8-K/A | [Amend] Current report |
| Aug 5, 2025 | 8-K | Current Report |
| Aug 4, 2025 | SCHEDULE 13G | Filing |
| Aug 4, 2025 | SCHEDULE 13G/A | Filing |
| Aug 1, 2025 | 8-K | Current Report |